Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity
Bicara was one of three biotechs that went public last week in one of the busiest biotech IPO windows this year.
IPO Industry
Global stock market crash likely to delay biotech IPOs
Money moves: How the biotech market is weathering inflationary storms
Valneva receives up to £20m vaccine R&D funding in Scotland
Covid-19 update: Yellen calls for new fund to tackle future health crises
Ventus Therapeutics raises funding to expedite drug discovery platform
Macro view: Covid-19 response did not lack funding
PharmaLex enters merger deal with Ascent Development Services
